Clinical application of gargle containing ELASE® to stomatitis due to radiation theraphy/anticances agent administration

K. Takamori, S. Asanami, J. Yokota, A. Kumagai, K. Tunoda, M. Okada, H. Kizu, Hideyuki Shiba, Y. Okada

Research output: Contribution to journalArticle

Abstract

Mucusomembrane inflammation is common during the treatment of oral cancer by radiation therapy and chemotherapy, and makes repeated application of these treatments difficult. The purpose of the present study was to evaluate the efficacy of the gargle containing ELASE® on alleviating this side effect. Eleven patients of oral cancer (radiation therapy alone: 9 cases, radiation therapy combined with chemotherapy: 2 cases) were evaluated. 5V of ELASE® was dissolved in 500 ml of the T-Caine/wasser, the standard prescription at our hospital (1% T-caine solution: 2 ml, simple syrup: 5 ml, 0.01% acrinol solution: 493 ml). Following the initiation of anticancer treatment, when pain at the oral mucosa appeared, 100 ml of the above standard regimen with ELASE® was given as gargle 4 to 5 times a day. The control group consisted of 11 patients treated with radiation therapy alone and gargle without ELASE®. During the study period, both subjective (bad breath, dry sensation dysgeusia, and pain) and objective (redness, erosion, and fetor) symptoms were evaluated. In the control group, these symptoms were found to be aggravated or unchanged while in the ELASE® gargle group, some patients demonstrated improvement in pain, erosion and fetor.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalOral Therapeutics and Pharmacology
Volume16
Issue number3
Publication statusPublished - 1997

Fingerprint

Stomatitis
Radiotherapy
Radiation
Mouth Neoplasms
Pain
Ethacridine
Dysgeusia
Drug Therapy
Control Groups
Mouth Mucosa
Prescriptions
Therapeutics
Inflammation
p-(butylamino)benzoic acid-2-(diethylamino)ethyl ester

Keywords

  • Elase® gargle
  • Mucositis
  • Oral cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Takamori, K., Asanami, S., Yokota, J., Kumagai, A., Tunoda, K., Okada, M., ... Okada, Y. (1997). Clinical application of gargle containing ELASE® to stomatitis due to radiation theraphy/anticances agent administration. Oral Therapeutics and Pharmacology, 16(3), 99-103.

Clinical application of gargle containing ELASE® to stomatitis due to radiation theraphy/anticances agent administration. / Takamori, K.; Asanami, S.; Yokota, J.; Kumagai, A.; Tunoda, K.; Okada, M.; Kizu, H.; Shiba, Hideyuki; Okada, Y.

In: Oral Therapeutics and Pharmacology, Vol. 16, No. 3, 1997, p. 99-103.

Research output: Contribution to journalArticle

Takamori, K, Asanami, S, Yokota, J, Kumagai, A, Tunoda, K, Okada, M, Kizu, H, Shiba, H & Okada, Y 1997, 'Clinical application of gargle containing ELASE® to stomatitis due to radiation theraphy/anticances agent administration', Oral Therapeutics and Pharmacology, vol. 16, no. 3, pp. 99-103.
Takamori, K. ; Asanami, S. ; Yokota, J. ; Kumagai, A. ; Tunoda, K. ; Okada, M. ; Kizu, H. ; Shiba, Hideyuki ; Okada, Y. / Clinical application of gargle containing ELASE® to stomatitis due to radiation theraphy/anticances agent administration. In: Oral Therapeutics and Pharmacology. 1997 ; Vol. 16, No. 3. pp. 99-103.
@article{2704a81e5eec49fd82bd076a2336a8d9,
title = "Clinical application of gargle containing ELASE{\circledR} to stomatitis due to radiation theraphy/anticances agent administration",
abstract = "Mucusomembrane inflammation is common during the treatment of oral cancer by radiation therapy and chemotherapy, and makes repeated application of these treatments difficult. The purpose of the present study was to evaluate the efficacy of the gargle containing ELASE{\circledR} on alleviating this side effect. Eleven patients of oral cancer (radiation therapy alone: 9 cases, radiation therapy combined with chemotherapy: 2 cases) were evaluated. 5V of ELASE{\circledR} was dissolved in 500 ml of the T-Caine/wasser, the standard prescription at our hospital (1{\%} T-caine solution: 2 ml, simple syrup: 5 ml, 0.01{\%} acrinol solution: 493 ml). Following the initiation of anticancer treatment, when pain at the oral mucosa appeared, 100 ml of the above standard regimen with ELASE{\circledR} was given as gargle 4 to 5 times a day. The control group consisted of 11 patients treated with radiation therapy alone and gargle without ELASE{\circledR}. During the study period, both subjective (bad breath, dry sensation dysgeusia, and pain) and objective (redness, erosion, and fetor) symptoms were evaluated. In the control group, these symptoms were found to be aggravated or unchanged while in the ELASE{\circledR} gargle group, some patients demonstrated improvement in pain, erosion and fetor.",
keywords = "Elase{\circledR} gargle, Mucositis, Oral cancer, Radiation therapy",
author = "K. Takamori and S. Asanami and J. Yokota and A. Kumagai and K. Tunoda and M. Okada and H. Kizu and Hideyuki Shiba and Y. Okada",
year = "1997",
language = "English",
volume = "16",
pages = "99--103",
journal = "Oral Therapeutics and Pharmacology",
issn = "0288-1012",
publisher = "Japanese Society of Oral Therapeutics and Pharmacology",
number = "3",

}

TY - JOUR

T1 - Clinical application of gargle containing ELASE® to stomatitis due to radiation theraphy/anticances agent administration

AU - Takamori, K.

AU - Asanami, S.

AU - Yokota, J.

AU - Kumagai, A.

AU - Tunoda, K.

AU - Okada, M.

AU - Kizu, H.

AU - Shiba, Hideyuki

AU - Okada, Y.

PY - 1997

Y1 - 1997

N2 - Mucusomembrane inflammation is common during the treatment of oral cancer by radiation therapy and chemotherapy, and makes repeated application of these treatments difficult. The purpose of the present study was to evaluate the efficacy of the gargle containing ELASE® on alleviating this side effect. Eleven patients of oral cancer (radiation therapy alone: 9 cases, radiation therapy combined with chemotherapy: 2 cases) were evaluated. 5V of ELASE® was dissolved in 500 ml of the T-Caine/wasser, the standard prescription at our hospital (1% T-caine solution: 2 ml, simple syrup: 5 ml, 0.01% acrinol solution: 493 ml). Following the initiation of anticancer treatment, when pain at the oral mucosa appeared, 100 ml of the above standard regimen with ELASE® was given as gargle 4 to 5 times a day. The control group consisted of 11 patients treated with radiation therapy alone and gargle without ELASE®. During the study period, both subjective (bad breath, dry sensation dysgeusia, and pain) and objective (redness, erosion, and fetor) symptoms were evaluated. In the control group, these symptoms were found to be aggravated or unchanged while in the ELASE® gargle group, some patients demonstrated improvement in pain, erosion and fetor.

AB - Mucusomembrane inflammation is common during the treatment of oral cancer by radiation therapy and chemotherapy, and makes repeated application of these treatments difficult. The purpose of the present study was to evaluate the efficacy of the gargle containing ELASE® on alleviating this side effect. Eleven patients of oral cancer (radiation therapy alone: 9 cases, radiation therapy combined with chemotherapy: 2 cases) were evaluated. 5V of ELASE® was dissolved in 500 ml of the T-Caine/wasser, the standard prescription at our hospital (1% T-caine solution: 2 ml, simple syrup: 5 ml, 0.01% acrinol solution: 493 ml). Following the initiation of anticancer treatment, when pain at the oral mucosa appeared, 100 ml of the above standard regimen with ELASE® was given as gargle 4 to 5 times a day. The control group consisted of 11 patients treated with radiation therapy alone and gargle without ELASE®. During the study period, both subjective (bad breath, dry sensation dysgeusia, and pain) and objective (redness, erosion, and fetor) symptoms were evaluated. In the control group, these symptoms were found to be aggravated or unchanged while in the ELASE® gargle group, some patients demonstrated improvement in pain, erosion and fetor.

KW - Elase® gargle

KW - Mucositis

KW - Oral cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0031418433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031418433&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031418433

VL - 16

SP - 99

EP - 103

JO - Oral Therapeutics and Pharmacology

JF - Oral Therapeutics and Pharmacology

SN - 0288-1012

IS - 3

ER -